Risk prediction models for targeted testing of HIV, hepatitis B and hepatitis C: a systematic review and meta-analysis

针对艾滋病毒、乙型肝炎和丙型肝炎的靶向检测风险预测模型:系统评价和荟萃分析

阅读:1

Abstract

BACKGROUND: Diagnosing human immunodeficiency virus (HIV), hepatitis B virus (HBV), and hepatitis C virus (HCV) infections in general population settings is challenging. We conducted a systematic review and meta-analysis of prediction tools designed to help identify individuals at risk of these blood-borne viruses. METHODS: We included studies on individuals of any age at risk of blood-borne viruses from healthcare, community settings, and national databases. We searched the Web of Science, MEDLINE, EMBASE, and CENTRAL databases (from database inception to 2023) and used the Prediction model Risk Of Bias ASsessment Tool (PROBAST) to evaluate the quality and systematic risk of bias of these studies. We extracted model accuracy using the area under the receiver operating characteristic curve (AUC), sensitivity, and specificity. A mixed-effects model (for AUC) and bivariate random-effects model (for sensitivity/specificity) were used to generate pooled values for these studies. RESULTS: Of the 41,585 records, 71 were included, covering over 31 million participants and more than 65,000 cases of blood-borne viruses. We examined 67 models: 47 for HIV, 13 for HCV, 5 for HBV, and 2 from studies that assessed multiple viruses separately. The studies were conducted in 41 low- and middle-income and 30 high-income countries. They covered 11 different populations (including men who have sex with men, the general population, and women), 8 types of settings (including sexual health, secondary care, and primary care) and 7 types of risk factors (behavioural, clinical, and demographic). The methods comprised traditional regression (n = 50), machine-learning models (n = 17), and others (n = 4). The risk of bias was high in 64 studies and low in seven. Among 33 studies reporting mean and 95% CI, pooled AUC values were 0.73 (95% CI:0.67–0.80, [Formula: see text] = 74%) across HIV studies (including 8 machine-learning models), 0.80 (0.73–0.86, [Formula: see text] = 86%) for HCV (including 2 machine-learning models) and 0.79 (0.76–0.81, [Formula: see text] = 93%) for HBV (including 3 machine-learning models). CONCLUSIONS: Significant heterogeneity exists in blood-borne virus prediction accuracy across diverse settings and populations, with a high risk of bias. Contributions from primary care were limited, and evaluation and reporting were inconsistent. Developing and evaluating effective models for the combined risk assessment of HIV, HBV, and HCV in general population settings remains a priority. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12879-025-11921-3.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。